These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 10896924

  • 1. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T.
    Gut; 2000 Aug; 47(2):288-95. PubMed ID: 10896924
    [Abstract] [Full Text] [Related]

  • 2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U.
    Hepatogastroenterology; 2003 Aug; 50(54):1753-5. PubMed ID: 14696397
    [Abstract] [Full Text] [Related]

  • 3. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J.
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [Abstract] [Full Text] [Related]

  • 4. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis.
    Song T, Rössle M, He F, Liu F, Guo X, Qi X.
    Dig Liver Dis; 2018 Apr; 50(4):323-330. PubMed ID: 29422242
    [Abstract] [Full Text] [Related]

  • 5. Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.
    Charilaou P, Devani K, Petrosyan R, Reddy C, Pyrsopoulos N.
    Dig Dis Sci; 2020 Nov; 65(11):3378-3388. PubMed ID: 32062714
    [Abstract] [Full Text] [Related]

  • 6. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 7. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
    Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A, Liver-HERO Study Group.
    Trials; 2023 Apr 05; 24(1):258. PubMed ID: 37020315
    [Abstract] [Full Text] [Related]

  • 8. Severe acute alcoholic hepatitis and hepatorenal syndrome: role of transjugular intrahepatic portosystemic stent shunt.
    Testino G, Leone S, Ferro C, Borro P.
    J Med Life; 2012 Jun 12; 5(2):203-5. PubMed ID: 22802893
    [Abstract] [Full Text] [Related]

  • 9. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D, Zuo H, Liu L, Dong J, Ding L.
    Virol J; 2018 Oct 01; 15(1):151. PubMed ID: 30285813
    [Abstract] [Full Text] [Related]

  • 10. Gender Disparity in Inpatient Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation in Patients Admitted With Hepatorenal Syndrome: A Nationwide Study.
    Trivedi PS, Brown MA, Rochon PJ, Ryu RK, Johnson DT.
    J Am Coll Radiol; 2020 Feb 01; 17(2):231-237. PubMed ID: 31541656
    [Abstract] [Full Text] [Related]

  • 11. Transjugular Intrahepatic Portosystemic Shunt Through the Strut of a Previously Placed Stent: Technical Feasibility and Long-Term Follow-Up Results.
    Ahmed M, Keshava SN, Moses V, Chiramel GK, Mammen S, Eapen CE, Zachariah UG.
    Cardiovasc Intervent Radiol; 2018 Nov 01; 41(11):1794-1798. PubMed ID: 30014251
    [Abstract] [Full Text] [Related]

  • 12. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial.
    Rosemurgy AS, Frohman HA, Teta AF, Luberice K, Ross SB.
    J Am Coll Surg; 2012 Apr 01; 214(4):445-53; discussion 453-5. PubMed ID: 22463885
    [Abstract] [Full Text] [Related]

  • 13. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.
    Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J.
    Gut; 2011 Jun 01; 60(6):846-52. PubMed ID: 21357252
    [Abstract] [Full Text] [Related]

  • 14. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK, James PD, Sniderman KW, Wong F.
    J Gastroenterol Hepatol; 2015 Feb 01; 30(2):389-95. PubMed ID: 25168607
    [Abstract] [Full Text] [Related]

  • 15. Review article: prognosis of hepatorenal syndrome--has it changed with current practice?
    Angeli P.
    Aliment Pharmacol Ther; 2004 Sep 01; 20 Suppl 3():44-6; discussion 47-8. PubMed ID: 15335400
    [Abstract] [Full Text] [Related]

  • 16. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function.
    Ponzo P, Campion D, Rizzo M, Roma M, Caviglia GP, Giovo I, Rizzi F, Bonetto S, Saracco GM, Alessandria C.
    Dig Liver Dis; 2022 Aug 01; 54(8):1101-1108. PubMed ID: 34625366
    [Abstract] [Full Text] [Related]

  • 17. [Hepatorenal syndrome].
    Huschak G, Kaisers UX, Laudi S.
    Anaesthesist; 2013 Jul 01; 62(7):571-82. PubMed ID: 23846211
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding.
    Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, Schiedermaier P, Schild HH, Sauerbruch T.
    Digestion; 2003 Jul 01; 67(3):146-53. PubMed ID: 12853726
    [Abstract] [Full Text] [Related]

  • 19. Outcomes after transjugular intrahepatic portosystemic stent shunt: a "bridge" to nowhere.
    Toomey PG, Ross SB, Golkar FC, Hernandez JM, Clark WC, Luberice K, Alsina AE, Rosemurgy AS.
    Am J Surg; 2013 Apr 01; 205(4):441-6. PubMed ID: 23375760
    [Abstract] [Full Text] [Related]

  • 20. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome.
    Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T.
    Lancet; 1997 Mar 08; 349(9053):697-8. PubMed ID: 9078203
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.